Related Experiment Video
Updated: Jul 17, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
Jak2: normal function and role in hematopoietic disorders
James N Ihle1, D Gary Gilliland
1Department of Biochemistry, St Jude Children's Research Hospital, Memphis, TN 38105, USA. james.ihle@stjude.org
Abstract:
Janus kinase 2 (Jak2) associates with cytokine receptors and is essential for signal transduction by mediating tyrosine phosphorylation. Kinase activity is regulated by a series of interactions beginning with the requirement to bind to specific domains in receptors, suppression of activation by the pseudokinase domain, and the requirement for phosphorylation within the activation loop. Recent studies have implicated de-regulation of Jak2 kinase activity by chromosomal translocations in hematopoietic tumors and mutations within the pseudokinase domain in a spectrum of myeloproliferative diseases.
Insights
Janus kinase 2 (Jak2) is crucial for cell signaling via cytokine receptors. Its activity is tightly regulated, but disruptions are linked to blood cancers like myeloproliferative diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Janus kinase 2 (Jak2) is a key enzyme in cytokine receptor signaling pathways.
- Jak2 mediates signal transduction through tyrosine phosphorylation.
- Its activity is regulated by receptor binding, the pseudokinase domain, and activation loop phosphorylation.
Purpose of the Study:
- To summarize the regulatory mechanisms of Janus kinase 2 (Jak2) activity.
- To highlight the role of Jak2 dysregulation in hematologic malignancies.
Main Methods:
- Literature review of recent studies on Jak2 regulation and function.
- Analysis of research implicating Jak2 in hematopoietic tumors and myeloproliferative diseases.
Main Results:
- Jak2 activity is controlled by interactions with cytokine receptors.
- The pseudokinase domain and activation loop phosphorylation are critical regulatory sites.
- Chromosomal translocations and pseudokinase domain mutations disrupt Jak2 regulation.
Conclusions:
- Dysregulated Jak2 kinase activity is a significant factor in the pathogenesis of myeloproliferative diseases.
- Understanding Jak2 regulation is vital for developing targeted therapies for blood cancers.
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Regulation of Hematopoietic Stem Cells
The JAK-STAT Signaling Pathway
Hematopoiesis
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Multipotency of Hematopoietic Stem Cells
